Groupe Hospitalier Saint Vincent — Clinical Trial Site

27 Registered trials

12 Currently recruiting

Organisation

Groupe Hospitalier Saint Vincent

Location

Strasbourg, France

Identifier

ORG-100045762

Address

182 Route De La Wantzenau, 67000, France

Departments

Centre de Radiotherapie
Clinique Saint Anne - Service Hematologie-Oncologie
Clinique Sainte Anne, Département d'Hématologie et d'Oncologie 184
Clinique Sainte Anne, Service d'Oncologie
Département d’oncologie
Hématologie-oncologie
Hôpital de jour - Oncologie Médicale
Medical Oncology
oncologie
Oncologie Médicale
Oncology
Service d'oncologie Libérale
Service d’Oncologie

Clinical trials at this site (27)

Search interface

A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending

2025-524488-18-00 Muscle-invasive Bladder Cancer 4
TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting

2024-516339-28-00 EGFR inhibitor-induced folliculitis 4 2025-02-10
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin… Recruiting

2025-521606-18-00 Ovarian Cancer 4 2026-01-29
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting

2024-517653-27-00 Prostate Cancer 4 2025-12-17
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials – p53abn - RED Randomized phase … Recruiting

2023-503886-44-00 Patients with a histological diagnosis of p53abn HREC, 5 2024-06-10
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended

2024-511202-23-00 Epithelial ovarian cancer that progressed on prior PARP 4 2024-10-31
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl… Ended

2023-509396-16-00 Metastatic Castration-Resistant Prostate Cancer 5 2021-11-08
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended

2024-510985-17-00 First Line Treatment in Subjects with Claudin 18.2 (CLD 4 2019-03-14
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29